<p>The tentative approval by the US Food & Drug Administration (USFDA) is for marketing of Donepezil HCl tablets in 5 mg and 10 mg strengths, which is used for treatment of Alzheimer's disease and dementia, the company said in a statement.<br /><br />Donepezil is the generic name for the brand Aricept, marketed in the US by Eisai in partnership with Pfizer.<br /><br />"Wockhardt will be launching the product in the US market on May 28, 2011," it said.<br />Citing IMS Health, the company said the total market for this product in the US is about USD 2.5 billion.<br /><br />Commenting on the approval, Wockhardt Chairman Habil Khorakiwala said: "We are continuing to get a steady stream of FDA approval and are able to launch them on the date the generic market opportunity opens."<br /><br />Wockhardt Ltd's scrip was trading at Rs 360.50 during mid-day trade on the Bombay Stock Exchange, up 2.33 per cent from the previous close.</p>
<p>The tentative approval by the US Food & Drug Administration (USFDA) is for marketing of Donepezil HCl tablets in 5 mg and 10 mg strengths, which is used for treatment of Alzheimer's disease and dementia, the company said in a statement.<br /><br />Donepezil is the generic name for the brand Aricept, marketed in the US by Eisai in partnership with Pfizer.<br /><br />"Wockhardt will be launching the product in the US market on May 28, 2011," it said.<br />Citing IMS Health, the company said the total market for this product in the US is about USD 2.5 billion.<br /><br />Commenting on the approval, Wockhardt Chairman Habil Khorakiwala said: "We are continuing to get a steady stream of FDA approval and are able to launch them on the date the generic market opportunity opens."<br /><br />Wockhardt Ltd's scrip was trading at Rs 360.50 during mid-day trade on the Bombay Stock Exchange, up 2.33 per cent from the previous close.</p>